CAJ | 학술논문

目的：探讨干扰素诱导的跨膜蛋白1（ IFITM1）在结直肠癌中的表达及临床意义。方法收集144例具有完整临床病理资料的结直肠腺癌组织标本，运用组织芯片技术和免疫组化法检测IFITM1在结直肠癌及其对应癌旁组织中的表达，分析IFITM1表达与临床病理特征、总生存时间（ OS）的关系，以及影响预后的因素。结果 IFITM1在结肠腺癌组织中的高、中、低表达率分别为7?7％、36?9％、55?4％，癌旁组织中分别为3?1％、27?7％、69?2％，差异有统计学意义（ P＝0?044）；IFITM1在直肠腺癌组织中高、中、低表达率分别为1?3％、39?2％、59?5％，在癌旁组织中分别为5?1％、36?9％、58?2％，差异无统计学意义（P＝0?569）。 IFITM1表达水平和结直肠癌组织分化有关（P＝0?031），与年龄、性别、淋巴结转移、远处转移及TNM分期等无关（ P＞0?05）。 IFITM1高、中、低表达结直肠癌患者的中位OS分别为34?3个月、45?7个月和46?7个月（ P＝0?700）；结肠癌患者的中位OS分别为38?2个月、48?0个月和43?5个月；直肠腺癌患者的中位OS分别为15?0个月、42?7个月和50?1个月（ P＝0?037）。单因素和多因素分析显示，IFITM1的表达水平不是影响结直肠癌预后的因素。结论结直肠癌组织中IFITM1表达与组织分化无关。
목적：탐토간우소유도적과막단백1（ IFITM1）재결직장암중적표체급림상의의。방법수집144례구유완정림상병리자료적결직장선암조직표본，운용조직심편기술화면역조화법검측IFITM1재결직장암급기대응암방조직중적표체，분석IFITM1표체여림상병리특정、총생존시간（ OS）적관계，이급영향예후적인소。결과 IFITM1재결장선암조직중적고、중、저표체솔분별위7?7％、36?9％、55?4％，암방조직중분별위3?1％、27?7％、69?2％，차이유통계학의의（ P＝0?044）；IFITM1재직장선암조직중고、중、저표체솔분별위1?3％、39?2％、59?5％，재암방조직중분별위5?1％、36?9％、58?2％，차이무통계학의의（P＝0?569）。 IFITM1표체수평화결직장암조직분화유관（P＝0?031），여년령、성별、림파결전이、원처전이급TNM분기등무관（ P＞0?05）。 IFITM1고、중、저표체결직장암환자적중위OS분별위34?3개월、45?7개월화46?7개월（ P＝0?700）；결장암환자적중위OS분별위38?2개월、48?0개월화43?5개월；직장선암환자적중위OS분별위15?0개월、42?7개월화50?1개월（ P＝0?037）。단인소화다인소분석현시，IFITM1적표체수평불시영향결직장암예후적인소。결론결직장암조직중IFITM1표체여조직분화무관。
Objective To examine the expression level of interferon?induced transmembrane protein1( IFITM1) and assess its clinical significance in colorectal cancer. Methods Tissue microarrays were constructed from 144 paraffin?embedded tissue blocks containing colorectal cancer with corresponding normal epithelium, and the expression of IFITM1 was tested by immunohistochemistry. The correlations between IFITM1 expression, the clinicopathological factors and overall survival rate were evaluated. Results Immuno?histochemistry demonstrated that strong ( 7?7%) , moderate ( 36?9%) and weak ( 55?4%) expression rate of IFITM1 in colonic cancer tissue were higher than those of adjacent noncancerous tissue( 7?7%,36?9% and 55?4%) ,with significant difference( P=0?044) . The strong ( 1?3%) , moderate ( 39?2%) and weak ( 59?5%) expression rate of IFITM1 in rectal adenocarcinoma showed no statistic sig?nificance compared with (5?1%, 36?9% and 58?2%), with no difference (P=0?569).The expression of IFITM1 was significantly correlated with histological differentiation ( P=0?031) . However, the gender, age, tumor location, depth of invasion, lymph node me?tastasis, and TNM stage had no significant correlation with IFITM1 expression. OS of colorectal cancer patients with high, moderate, low expression of IFITM1 were 34?3, 45?7 and 46?7 months( P=0?700) . Moreover, Kaplan?Meier survival analysis demonstrated that patients with higher IFITM1 expression had worse overall survival outcomes than those with lower levels of IFITM1 expression in rectal cancer ( P=0?037) . Mean survival of rectal cancer patients with IFITM1 high expression, moderate expression and low expression was 15?0, 42?7 and 50?1 months respectively. IFITM1 expression was not a significant negative prognostic factor for survival by univariate or multivariate analyses. Conclusion The results suggest that the expression of IFITM1 is associated with poor prognosis in rectal ade?nocarcinoma. IFITM1 may be a biomarker to predict prognosis in patients with rectal adenocarinoma.